Biotech Values

[floblu14]

Momenta Pharmaceuticals Reports Financial Results for the
Fourth Quarter and Year End 2009

CAMBRIDGE, Mass., Feb. 11, 2010 (GLOBE NEWSWIRE) -- Momenta
Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company
specializing in the characterization and engineering of complex drugs,
today reported its financial results for the fourth quarter and year
ended December 31, 2009.

For the fourth quarter of 2009 the Company reported a net loss of $14.7
million, compared to a net loss of $18.4 million for the same period in
2008. For the year ended December 31, 2009, the Company reported a net
loss of $64.0 million compared to a net loss of $62.6 million for the
same period in 2008. At December 31, 2009, the Company had cash, cash
equivalents, and marketable securities of $95.7 million, compared to
$108.5 million at December 31, 2008.

"Momenta is poised for a pivotal year in 2010," commented Craig A.
Wheeler, President and Chief Executive Officer. "We continue to believe
the FDA will approve the ANDA for generic Lovenox(R). Together with our
collaborative partner Sandoz, we are prepared for a potential launch.
The FDA review of the ANDA for the second complex mixture product in
our pipeline, generic Copaxone(R), is also well underway. Our novel
drug candidates, products of Momenta's proprietary analytical platform,
are advancing. We begin 2010 financially strong and committed to
developing needed medications that will deliver value to patients," he
concluded.

2009 Highlights:


-- In 2009 the FDA continued to review the ANDA for M-Enoxaparin, a generic
version Lovenox. During the year the agency inspected the manufacturing
supply chain and, we believe, we have now satisfactorily resolved all of
the outstanding technical and regulatory issues relating to approval.
-- We made considerable progress in the regulatory, product and process
development activities required to support the approval and
commercialization for M356, a generic version of Copaxone.
-- We announced positive Phase 2a study results for M118, Momenta's novel
anticoagulant, supporting its potential to become the baseline
anticoagulant of choice for patients with acute coronary syndromes
(ACS).
-- We presented preclinical data for M402, a novel oncology product
candidate, at the American Association for Cancer Research meeting.
M402, a rationally designed molecule with a novel mechanism of action,
was shown to inhibit tumor metastasis in two murine models, providing a
rationale for further clinical development.
-- The Momenta Board of Directors was strengthened with the addition of
Bruce L. Downey, former Chairman and CEO of Barr Laboratories.
-- We completed a $46.8 million follow-on offering of Momenta stock.




Financial Results

Revenue for the fourth quarter of 2009 was $5.6 million, compared to
$2.9 million for the same period in 2008. For the year ended December
31, 2009, revenue was $20.2 million, compared to $14.6 million for
2008. The increase in revenue in both periods was a result of an
increase in reimbursable expenses associated with the development of
our M356 program.

Research and development expenses for the fourth quarter of 2009 were
$14.2 million, compared to $15.4 million for the same period in 2008.
The decrease in research and development expenses from fourth quarter
2008 to fourth quarter 2009 principally resulted from a decrease in
clinical development costs associated with the completion of the M118
Phase 2a clinical trial in June 2009. For the year ended December 31,
2009, research and development expenses were $60.6 million, compared to
$55.3 million for 2008. The year-over-year increase in research and
development expenses was primarily due to increased manufacturing and
third-party research and development expenditures associated with our
M356 program.

General and administrative expenses for the fourth quarter of 2009
totaled $6.1 million, compared with $6.2 million for the same period in
2008. For the year ended December 31, 2009, general and administrative
expenses were $23.8 million, compared to $24.6 million for 2008. The
decrease in general and administrative expenses for the year was
primarily due to a decrease in professional fees.